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subscales results. The best performing models were selected 
based on mean absolute error (MAE) and root-mean square 
error (RMSE).
Results EQ-5D-5L and FAACT/FACIT-F results were 
available for 96 patients. The developed algorithms showed 
a good predictive performance, with acceptable MAE/
RMSE and small differences between mean observed and 
predicted EQ-5D-5L utilities. In FACT-G models, Physical 
Well-Being had the highest explanatory value, while Emo-
tional Well-Being did not significantly affect the EQ-5D-5L 
score; Anorexia-Cachexia and Fatigue subscales were highly 
statistically significant in FAACT and FACIT-F models, 
respectively, as well as the TOI scores. The Eastern Coop-
erative Oncology Group status was included as covariate in 
all models.
Conclusion The developed algorithms enable the estima-
tion of EQ-5D-5L utilities from three cancer-specific instru-
ments when preference-based HRQoL data are missing.
Keywords Mapping · FAACT · FACIT-F · FACT-G · 
EQ-5D-5L · Non-small cell lung cancer cachexia
JEL Classification C2 · I1
Introduction
Cachexia has been defined as “a complex metabolic syn-
drome associated with underlying illness and characterized 
by the loss of muscle with or without the loss of fat mass” 
[1]. Cachexia is a common clinical manifestation in cancer, 
especially at advanced stages. The frequency of this syn-
drome in lung cancer consistently outweighs that in other 
malignancies [2]. Cachectic patients experience a wide range 
of symptoms including lack of appetite, early satiety, and 
Abstract 
Background Health-related quality of life (HRQoL) meas-
urements from disease-specific tools cannot be directly 
used in economic evaluations. This study aimed to develop 
and validate mapping algorithms that predicted EuroQol 
5-Dimensions 5-Levels (EQ-5D-5L) utilities from Func-
tional Assessment of Anorexia-Cachexia Therapy (FAACT) 
and Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) and their common component (Func-
tional Assessment of Cancer Therapy-General—FACT-G) 
in patients with non-small cell lung cancer cachexia.
Methods Data were collected on five occasions over a 
12-week period in two multicenter placebo-controlled tri-
als. EQ-5D-5L utilities were calculated using both English 
and Dutch value sets. The study sample was divided into 
development and validation datasets according to patients’ 
geographical residence. Generalized estimating equations 
were applied to five different sets of independent variables 
including overall, Trial Outcome Index (TOI), and individual 
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impaired physical functioning, which cumulatively decrease 
their quality of life and worsen their prognosis. Indeed, 
cachexia is estimated to be the direct cause of at least 20% 
of cancer deaths [3, 4].
The questionnaires belonging to the functional assess-
ment of chronic illness therapy (FACIT) measurement sys-
tem [5] are frequently adopted to estimate health-related 
quality of life (HRQoL) in cancer studies. The functional 
assessment of cancer therapy-general (FACT-G) can be used 
in any tumor type and constitutes the core of all other ques-
tionnaires addressing the specific concerns of patients with 
various malignancies. Among them, the functional assess-
ment of anorexia/cachexia treatment (FAACT) has been 
recommended in the assessment of cancer-related cachexia 
[6]. The questionnaire may be administered in conjunction 
with others such as the functional assessment of chronic ill-
ness therapy-fatigue (FACIT-F), which is specifically aimed 
at measuring fatigue symptoms in chronic diseases. How-
ever, these questionnaires do not provide preference-based 
scores (utilities) that are essential in the quality-adjusted life 
years (QALYs) calculation for cost-effectiveness analyses. 
Conversely, the EuroQol five-dimensional (EQ-5D) ques-
tionnaire, developed by the group EuroQol [7], furnishes 
preference weights from the general population to derive 
QALYs and has been endorsed as a health utility standard by 
the National Institute for Health and Care Excellence (NICE) 
in England [8].
The measurement of HRQoL in oncology is mostly 
carried out using cancer-specific instruments rather than 
generic preference-based measures as they focus on relevant 
health issues and tend to capture more meaningful changes 
in symptomatology [9]. In a systematic literature review of 
studies addressing HRQoL in cancer anorexia-cachexia syn-
drome [10], FAACT was endorsed by seven studies, one of 
them reporting also the common core component (FACT-G), 
while only four studies adopted the generic EQ-5D instru-
ment. In the absence of preference-based scores, statistical 
models that ”map”, or “cross-walk”, the responses from 
a disease-specific instrument to utility values can be used 
as an alternative solution. In recent years, there has been a 
growing interest in mapping, with a number of published 
algorithms predicting EQ-5D health utilities from a wide 
range of disease-specific, non-preference-based scores [11]. 
A database maintained by the Health Economics Research 
Centre (Oxford University) [12] and regularly updated with 
all mapping studies published in the literature yielded 24 
algorithms estimating EQ-5D scores from cancer-specific 
instruments; among them, eight studies adopted a question-
naire from the FACIT group to address a variety of tumors 
(breast, prostate, colorectal, lung, and melanoma). However, 
no algorithm exists specifically for anorexia-cachexia cancer 
syndrome, thus making it difficult for regulatory bodies to 
assess the QALY gain of new treatments for the purpose of 
reimbursement in the absence of generic preference-based 
data collections. The objective of this study was to develop 
a reliable mapping function to estimate the 5-level EQ-5D 
(EQ-5D-5L) utility values from FACT-G, FAACT, and 
FACIT-F scores to inform future cost-effectiveness analyses 
in the cancer cachexia setting or in lung cancer.
Methods
In performing this study, we referred to the recently pub-
lished MAPS reporting statement [13] and completed the 
proposed 23-item checklist for mapping studies (Table A1, 
online appendix).
Study sample
Data from two multicenter, randomized, double blind, pla-
cebo-controlled phase 3 trials (ROMANA 1 and ROMANA 
2) in patients with non-small cell lung cancer-cachexia 
(NSCLC-C) were used for this analysis. The trials were 
conducted at 93 sites in 19 countries between 2011 and 
2014. The two studies enrolled a total of 979 patients aged 
≥18 years with a diagnosis of stage III or IV NSCLC and 
cachexia [defined as involuntary loss of ≥5% body weight 
within 6 months or body mass index (BMI) <20 kg/m2]; 
patients had an estimated life expectancy of more than 
4 months at enrollment and a Eastern Cooperative Oncology 
Group (ECOG) performance status ≤2. Details of the inclu-
sion/exclusion criteria and the study design are described 
elsewhere [14]. Patients were randomly assigned 2:1 to 
receive active treatment (100 mg, Anamorelin HC1, Helsinn 
Therapeutics, Inc.) or placebo once daily over a 12-week 
period. Primary efficacy endpoints were the median change 
in lean body mass and handgrip strength over the same 
period. Among the secondary efficacy parameters, HRQoL 
was assessed by FACIT-F and FAACT (version 4) at base-
line and weeks 3, 6, 9, and 12. Moreover, the EQ-5D-5L 
questionnaire was administered at the same time points to 
a subset of patients in only two sites (i.e. Poland and Hun-
gary). For the purpose of this analysis, we used the sample 
of observations reporting both HRQoL instruments (i.e. 
FACIT-F/FAACT and EQ-5D-5L) without any distinction 
between the treatment arms.
Instruments
The EQ-5D-5L questionnaire is a generic, preference-based 
HRQoL measure comprising five domains: mobility, self-
care, usual activities, pain/discomfort, and anxiety/depres-
sion [7]. Each dimension has five levels: no problems, slight 
problems, moderate problems, severe problems, and extreme 
problems. Patients’ responses to the questionnaire were 
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scored using the English EQ-5D-5L value set [15], which 
ranges from −0.281 (state 55555) and 1 (state 11111, rep-
resenting perfect health) and the Dutch EQ-5D-5L value set 
[16] ranging between −0.446 and 1 to illustrate the sensitiv-
ity of results to the use of alternative value sets.
The FAACT is the anorexia-cachexia-specific HRQoL 
instrument of the FACIT system [5]. It comprises the 
27-item FACT-G and a 12-item Anorexia-Cachexia Subscale 
(ACS). Each item is rated on a 5-point Likert scale (from 0 
to 4) ranging from “not at all” to “very much”. The FAACT 
is the sum of the FACT-G score (0–108) and the ACS score 
(0–48) with higher values representing better health. Simi-
lar to FAACT, the FACIT-F comprises the FACT-G and 
a 13-item Fatigue Subscale (0–52), yielding a total score 
between 0 and 160. The FACT-G is composed of four sub-
scales assessing physical wellbeing (PWB, 0–28), functional 
wellbeing (FWB, 0–28), social/family well-being (SWB, 
0–28), and emotional wellbeing (EWB, 0–24). From these 
scales, it is also possible to calculate a Trial Outcome Index 
(TOI), which is the sum of PWB, FWB, and tool-specific 
subscales (in this study, ACS and Fatigue).
Statistical analysis
Generalized estimating equations (GEEs) were performed 
in order to derive mapping functions for FAACT, FACIT-F, 
and FACT-G. GEE is a technique facilitating the analysis of 
data collected in longitudinal, clustered, or repeated meas-
ures designs, which is increasingly applied in clinical trials 
and biomedical studies. GEE is a population-level approach 
based on a quasi-likelihood function that provides the pop-
ulation-averaged estimates of the parameters. GEEs use the 
generalized linear model to estimate regression parameters 
allowing the specification of a working correlation matrix 
that accounts for the type of within-subject correlation of 
responses on the dependent variable [17, 18]. The GEE 
method was selected because of the longitudinal nature of 
the ROMANA trials, where repeated observations from each 
instrument are expected to be correlated between visits. This 
method has been used previously to predict EQ-5D utilities 
from the Functional Assessment of Cancer Therapy-Prostate 
(FACT-P) using data from a multicenter, randomized, pla-
cebo-controlled trial [19]. Quasi-likelihood under the inde-
pendence model criterion (QIC) statistics were calculated in 
order to select the best-working correlation structure [20].
In order to identify the best model specification, five 
alternative sets of explanatory variables were compared. 
Models were developed in order of increasing complexity 
given by the level of disaggregation of FACIT question-
naires scores. In detail, EQ-5D-5L scores were predicted 
from the overall FACT-G, FAACT, and FACIT-F scores 
(Model 1), from the generic (FACT-G) and specific (ACS 
and Fatigue) components separately (Model 2), from the 
four domains that compose FACT-G (PWB, FWB, SWB, 
and EWB) (Model 3), from the TOI score alone (Model 
4) and from the three components (PWB, FWB, and ACS 
or Fatigue) of TOI scores (Model 5). Selected clinical and 
demographic variables were tested for potential inclusion in 
the final models on the basis of their statistical significance. 
These variables were: age (>65 or ≤65), gender, body mass 
index (BMI; ≤18.5 or >18.5 kg/m2), ECOG (0–1 or 2) per-
formance at baseline, weight loss in previous 6 months (> 
or ≤10% of body weight) and current chemotherapy/radio-
therapy status (yes or no). The great majority (99.0%) of the 
patients enrolled were white, thus ethnicity was not consid-
ered as a covariate in the regression models [21]. Squared 
FACIT scores were tested as well to allow for nonlinear rela-
tionships with EQ-5D-5L utility. No imputation of missing 
values was performed in order to avoid assumptions about 
regarding early patient dropout. No interactions were tested, 
as previous research demonstrated that adding interaction 
terms seldom improved the model fit [11, 21, 22] and the 
“principle of parsimony” should be embraced in developing 
mapping algorithms so that they can be more readily used by 
future researchers [23]. Pearson’s correlation was performed 
to estimate the degree of conceptual overlap between the 
source(s) and target measures that justified a mapping exer-
cise among them (Table A2, online appendix).
Model selection and cross‑validation
The performance of each model was assessed in terms of 
how well the responses to FACT-G, FAACT, and FACIT-F 
predicted EQ-5D-5L utilities. An out-of-sample validation 
is usually recommended to test the algorithms; however, no 
external datasets were available and an internal cross-vali-
dation technique was applied to derive goodness-of-fit sta-
tistics. The study sample was non-randomly divided into two 
groups using one-fifth (validation sample) four-fifths (devel-
opment sample) split according to patients’ geographical 
residence (i.e. Poland or Hungary). Following the approach 
of a previous study [24] and recommendations from the 
MAPS statement [13], we assumed that a non-random split 
ensures a more efficient validation, as the two groups are 
likely to differ according to some baseline characteristics. 
Statistical tests (i.e. Chi-squared for categorical variables 
and t test for continuous variables) were performed in order 
to explore the differences between the two sub-samples. 
Mapping functions were fitted on the development sample, 
while the remaining observations were used to test the mod-
els’ performance.
Model validation was performed by pooling all the vis-
its together in order to obtain average performance indexes 
within the database. The mean absolute error (MAE) and 
root-mean square error (RMSE) were calculated to exam-
ine the differences between mean observed and predicted 
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EQ-5D-5L scores, with lower values indicating better algo-
rithm performance. The MAE is the average of absolute dif-
ferences between observed and predicted utilities, while the 
RMSE is the root of the average of the squared differences. 
A paired t test (p < 0.05) was also applied to the differ-
ences between observed and mapped EQ-5D-5L scores with 
significant results indicating low predictive accuracy [25]. 
The best performing models were selected on the basis of 
the lowest MAE/RMSE results. Moreover, these differences 
were compared to the minimal important difference (MID) 
in EQ-5D utility that, in cancer patients, has been estimated 
as 0.08 using the UK value set for the 3-level version (EQ-
5D-3L) [26].
All analyses were conducted using STATA version 14.1 
(College Station, TX, USA) and Microsoft Excel 2013.
Results
Descriptive statistics
Demographic and baseline clinical data stratified by over-
all, development, and validation dataset are reported in 
Table 1. Overall, 96 patients completed both EQ-5D-5L 
and FACIT questionnaires; the number of observations per 
patient ranged between 1 and 5, for a total of 420 of which 
332 were used to develop the algorithms and the remaining 
88 for validating them. In the overall sample (n = 96), the 
majority of patients were male (68.7%) and their mean age 
was 61 years; most (86.5%) were on chemotherapy or radio-
therapy treatments. The average EQ-5D-5L utility at base-
line was 0.766 (SD = 0.19), ranging between −0.102 and 
1 (perfect health); mean FACT-G, FAAC,T and FACIT-F 
overall scores were 64.9 (SD = 14.2), 93.2 (SD = 21.0), and 
93.2 (SD = 22.4), respectively. Among FACT-G subscales, 
SWB had the highest score (20.5 ± 4.7), whilst EWB had 
the lowest (13.4 ± 5.0).
Patients in the development (n = 76, Poland) and valida-
tion (n = 20, Hungary) samples differed by BMI (kg/m2), 
weight loss, ECOG performance score and chemotherapy/
radiotherapy status at baseline. Significant differences 
(p < 0.05) in baseline HRQoL scores were only observed in 
mean EQ-5D-5L (both for English and Dutch values), FWB 
and Fatigue scores. Full descriptive statistics of EQ-5D-5L, 
FAACT and FACIT-F scores by visit for the overall sample 
are shown in Table 2. The distribution of EQ-5D-5L scores 
is shown in Fig. 1.
Regression models
Table 3a, b shows parameter estimates for all mapping func-
tions obtained from the development sample (76 patients, 
332 observations) using the English and Dutch value sets, 
respectively. Models with squared terms showed poorer 
goodness-of-fit (i.e. higher QIC) compared to models with-
out and accordingly were not retained in the analyses (results 
not shown). Based on QIC results, autoregressive correlation 
was chosen within the GEE model by assuming that repeated 
measures were more strongly correlated when close together 
in time. The preliminary analyses testing all demographic 
and clinical variables are not reported; among them, only 
ECOG performance status (score = 2 vs. score = 0–1) was 
included in the final models after backward selection, with 
higher ECOG scores predicting lower EQ-5D-5L utility val-
ues (negative coefficient; p < 0.001).
For all three FACIT instruments (FACT-G, FAACT, and 
FACIT-F), overall scores were highly significant (p < 0.001), 
as were the TOI scores, in models using aggregate results 
(Model 1 and Model 4). In models using the separate indi-
vidual subscales (Model 3 and Model 5), the EWB subscale 
was never significantly associated with the EQ-5D-5L score; 
conversely, PWB had the highest explanatory value with 
the exception of FACIT-F Model 3, where it was not sig-
nificant (p > 0.05). When ACS and Fatigue subscales were 
combined with the generic FACT-G score in models 2, the 
generic score was not significant in the FACIT-F model, 
implying that Fatigue and ECOG were sufficient to predict 
EQ-5D results. In all models, the coefficients of the HRQoL 
scales had the expected (positive) signs, indicating that bet-
ter health reported by disease-specific FACT-G/FAACT/
FACIT-F tools was associated with higher EQ-5D utility. 
The only exception was SWB that presented a negative coef-
ficient in all models, but its value was at the limits of statisti-
cal significance.
Model selection
A synthesis of model performances across all visits in the 
validation sample is reported in Table 4a, b comparing 
observed and predicted EQ-5D-5L utilities using English 
and Dutch preference weights, respectively. Overall, the 
mapping algorithms predicted well. The absolute differ-
ences between mean observed and mean predicted EQ-
5D-5L utilities were far below the MID of 0.08 reported 
for EQ-5D-3L in cancer studies [26]. Moreover, none of 
the estimates fell outside the theoretical range of EQ-5D-5L 
(i.e. −0.281, 1.000) with the exception of FACIT-F Model 
3 (UK), but only just (i.e. 1.014). Most of the t-test com-
parisons between observed and mapped scores yielded a 
non-significant p value (<0.05). However, all differences 
between observed and predicted values were negative, due 
to an overall tendency towards over-prediction in the poor-
est health states (EQ-5D-5L utility ≤0.700). At the same 
time, the range of predicted EQ-5D-5L utilities was gener-
ally narrower than the observed values and the algorithms 
failed to predict the value of 1 corresponding to perfect 
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health especially when using FACT-G and FAACT, whilst 
considerably larger intervals were obtained through FACIT-
F regression models.
Best performing algorithms were identified for each 
FACIT questionnaire according to the lowest MAE/RMSE 
scores, namely Models 3 for FACT-G and FAACT, and 
Table 1  Sample characteristics and HRQoL scores (at baseline) stratified by study dataset
SD standard deviation; BMI body mass index, ECOG Eastern Cooperative Oncology Group, FACT-G functional assessment of cancer therapy-
general, FAACT functional assessment of anorexia/cachexia treatment, FACIT-F functional assessment of chronic illness therapy-fatigue, PWB 
physical wellbeing, FWB functional wellbeing, EWB emotional wellbeing, SWB social/family wellbeing, ACS Anorexia-Cachexia Subscale, TOI 
trial outcome index, EQ-5D-5L EuroQol five-dimension five-level, UK United Kingdom, NL Netherlands
*p value <0.05
**p value <0.01
***p value <0.001
a T test
b Chi-square test
Variable Statistics Total sample (n = 96) Development 
sample (n = 76)
Validation sam-
ple (n = 20)
p value
Demographic and clinical data
 Country Poland [N (%)]
Hungary [N (%)]
76 (79.2)
20 (20.8)
76 (100.0)
0 (0.0)
0 (0.0)
20 (100.0)
 Age (years) Mean (±SD)
Range (min, max)
61.1 (±8.7)
36, 85
61.3 (±9.0)
36, 85
60.5 (±7.7)
46, 80
0.7217a
 Gender Male [N (%)] 66 (68.7) 54 (71.0) 12 (60.0) 0.343b
 BMI (Kg/m2) ≤18.5 [N (%)] 7 (7.29) 3 (3.95) 4 (20.0) 0.014b*
 Weight loss (in previous 6 months) >10% of body weight
[N (%)]
39 (40.6) 25 (32.9) 14 (70.0) 0.003b,**
 ECOG 0–1 [N (%)]
2 [N (%)]
78 (81.2)
18 (18.8)
58 (76.3)
18 (23.7)
20 (100.0)
0 (0.0)
0.016b,*
 On chemotherapy/radiotherapy Yes [N (%)] 83 (86.5) 74 (97.4) 9 (45.0) 0.000b,***
HRQoL scores (at baseline)
 FAACT Mean (± SD)
Range (min, max)
93.2 (±21.0)
28.0, 141.0
93.4 (±21.8)
28.0, 141.0
92.6 (±17.8)
47.8, 129.0
0.8774a
 FACIT-F Mean (±SD)
Range (min, max)
93.2 (±22.4)
20.0, 140.0
92.6 (±23.2)
20.0, 140.0
95.4 (±19.6)
57.8, 134.0
0.6274a
 FACT-G Mean (±SD)
Range (min, max)
64.9 (±14.2)
18.0, 95.0
65.4 (±14.7)
18.0, 95.0
63.0 (±12.0)
36.8, 88.0
0.5086a
 PWB Mean (±SD)
Range (min, max)
16.2 (±5.1)
4.0, 28.0
15.7 (±5.2)
4.0, 28.0
17.8 (±4.3)
11.0, 27.0
0.0976a
 FWB Mean (±SD)
Range (min, max)
14.8 (±5.3)
1.0, 26.0
15.8 (±4.9)
3.0, 26.0
11.0 (±5.4)
1.0, 21.0
0.0003a,**
 SWB Mean (±SD)
Range (min, max)
20.5 (±4.7)
4.0, 28.0
20.6 (±5.0)
4.0, 28.0
19.8 (±3.5)
12.8, 26.0
0.4864a
 EWB Mean (±SD)
Range (min, max)
13.4 (±5.0)
0.0, 24.0
13.2 (±5.4)
0.0, 24.0
14.3 (±3.5)
7.0, 21.0
0.3800a
 FAACT (ACS) Mean (±SD)
Range (min, max)
28.3 (±9.0)
5.0, 46.0
28.0 (±9.4)
5.0, 46.0
29.5 (±7.4)
11.0, 43.0
0.4957a
 FACIT-F (fatigue) Mean (±SD)
Range (min, max)
28.3 (±9.8)
2.0, 49.0
27.2 (±9.9)
2.0, 49.0
32.3 (±8.2)
17.0, 46.0
0.0360a,*
 FAACT (TOI) Mean (±SD)
Range (min, max)
59.3 (±15.9)
23.0, 99.0
59.5 (±16.3)
23.0, 99.0
58.4 (±14.5)
26.0, 85.0
0.7840a
 FACIT-F (TOI) Mean (±SD)
Range (min, max)
59.3 (±16.9)
15.0, 98.0
58.8 (±17.2)
15.0, 98.0
61.2 (±16.1)
36.0, 90.0
0.5643a
 EQ-5D-5L (UK index) Mean (±SD)
Range (min, max)
0.766 (±0.19)
−0.102, 1.000
0.746 (±0.20)
−0.102, 1.000
0.841 (±0.13)
0.527, 1.000
0.0478a,*
 EQ-5D-5L (NL index) Mean (±SD)
Range (min, max)
0.702 (±0.23)
−0.289, 1.000
0.678 (±0.25)
−0.289, 1.000
0.792 (±0.15)
0.383, 1.000
0.0514a,*
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Table 2  Descriptive statistics of HRQoL observed scores by study visits (overall sample)
Instrument Statistics Baseline Week 3 Week 6 Week 9 Week 12
 FAACT (overall)
Theoretical range (min, max): 0, 156
N 96 89 85 78 76
Mean (±SD) 93.2 (±21.0) 100.5 (±22.6) 101.5 (±21.2) 100.3 (±20.7) 95.3 (±23.6)
Range (min, max) 28.0, 141.0 57.0, 148.0 41.0, 147.7 55.3, 152.0 45.5–156.0
% floor, % ceiling 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 1.3
 FACIT-F (overall)
Theoretical range (min, max): 0, 160
N 96 89 85 78 75
Mean (±SD) 93.2 (±22.4) 99.2 (±24.4) 99.1 (±23.0) 97.1 (±21.9) 92.0 (±26.2)
Range (min, max) 20.0, 140.0 34.3, 154.0 37.0, 146.0 51.3, 156.0 13.5, 160.0
% floor, % ceiling 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 1.3
 FACT-G
Theoretical range (min, max): 0, 108
N 96 89 85 78 76
Mean (±SD) 64.9 (±14.2) 69.1 (±15.4) 69.3 (±14.1) 68.2 (±13.7) 64.6 (±16.3)
Range (min, max) 18.0, 95.0 31.3, 102.0 33.0, 101.7 41.0, 104.0 12.5, 108.0
% floor, % ceiling 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 1.3
 PWB
Theoretical range (min, max): 0, 28
N 96 90 86 78 76
Mean (±SD) 16.2 (±5.1) 17.1 (±5.6) 17.5 (±5.8) 17.1 (±5.3) 16.3 (±5.9)
Range (min, max) 4.0, 28.0 1.0, 28.0 1.0, 28.0 3.0, 28.0 0.0, 28.0
% floor, % ceiling 0.0, 1.0 0.0, 2.2 0.0, 2.3 0.0, 3.8 1.3, 3.9
 FWB
Theoretical range (min, max): 0, 28
N 96 90 85 78 76
Mean (±SD) 14.8 (±5.3) 15.8 (±5.5) 15.7 (±5.4) 15.5 (±4.7) 14.7 (±5.4)
Range (min, max) 1.0, 26.0 0.0, 27.0 3.0, 28.0 4.0, 27.0 2.0, 28.0
% floor, % ceiling 0.0, 0.0 1.1, 0.0 0.0, 1.2 0.0, 0.0 0.0, 1.3
 SWB
Theoretical range (min, max): 0, 28
N 96 90 86 78 76
Mean (±SD) 20.5 (±4.7) 21.1 (±4.4) 20.9 (±4.2) 20.6 (±4.4) 20.4 (±4.2)
Range (min, max) 4.0, 28.0 9.3, 28.0 8.0, 28.0 9.0, 28.0 10.5, 28.0
% floor, % ceiling 0.0, 5.2 0.0, 8.9 0.0, 5.8 0.0, 5.1 0.0, 10.5
 EWB
Theoretical range (min, max): 0, 24
N 96 89 85 78 76
Mean (±SD) 13.4 (±5.0) 14.9 (±4.7) 15.1 (±4.5) 14.9 (±4.3) 13.3 (±5.4)
Range (min, max) 0, 24 4, 24 1, 23 6, 24 0, 24
% floor, % ceiling 2.1, 2.1 0.0, 1.1 0.0, 0.0 0.0, 1.3 1.3, 2.6
 FAACT (ACS)
Theoretical range (min, max): 0, 48
N 96 90 86 78 76
Mean (±SD) 28.3 (±9.0) 31.4 (±9.3) 32.1 (±8.4) 32.2 (±8.9) 30.7 (±9.3)
Range (min, max) 5.0, 46.0 8.0, 47.0 8.0, 47.0 10.0, 48.0 8.0, 48.0
% floor, % ceiling 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 1.3 0.0, 2.6
 FACIT-F (Fatigue)
Theoretical range (min, max): 0, 52
N 96 90 86 78 75
Mean (±SD) 28.3 (±9.8) 30.2 (±10.8) 29.8 (±10.4) 29.0 (±10.1) 27.8 (±10.9)
Range (min, max) 2.0, 49.0 3.0, 52.0 1.0, 50.0 6.0, 52.0 1.0, 52.0
% floor, % ceiling 0.0, 0.0 0.0, 1.1 0.0, 0.0 0.0, 2.6 0.0, 1.3
 FAACT (TOI)
Theoretical range (min, max): 0, 104
N 96 89 85 78 76
Mean (±SD) 59.32 (±15.88) 64.51 (±17.16) 65.44 (±16.71) 64.79 (±15.68) 61.60 (±17.46)
Range (min, max) 23, 99 24, 98 12, 100 21, 102 28, 104
% floor, % ceiling 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 1.3
 FACIT-F (TOI)
Theoretical range (min, max): 0, 108
N 96 89 85 78 75
Mean (±SD) 59.29 (±16.95) 63.26 (±18.98) 63.06 (±18.47) 61.61 (±17.13) 58.47 (±19.89)
Range (min, max) 15, 98 13, 104 8, 98 17, 106 3, 108
% floor, % ceiling 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 0.0 0.0, 1.3
 EQ-5D-5L utility (UK index)
Theoretical range (min, max): −0.281, 
1
N 96 88 85 77 74
Mean (±SD) 0.766 (±0.19) 0.792 (±0.18) 0.790 (±0.19) 0.794 (±0.16) 0.760 (±0.22)
Range (min, max) −0.102, 1.000 0.103, 1.000 −0.218, 1.000 0.338, 1.000 −0.213, 1.000
% floor, % ceiling 0.0, 10.4 0.0, 18.2 0.0, 18.8 0.0, 18.2 0.0, 17.6
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Model 4 for FACIT-F (both for English and Dutch values). 
Scatterplots displaying observed and predicted EQ-5D-5L 
utility scores for the three best performing models applied 
to the validation sample (20 patients, 88 observations) are 
shown in Fig. 1a, b.
Discussion
In the absence of EQ-5D or other preference-based HRQoL 
measurements, mapping is a useful tool in order to estimate 
utility values to be adopted in cost-effectiveness analyses. 
Over the past decade, there has been a rapid increase of map-
ping studies predicting generic preference-based scores from 
non-preference based, disease-specific results. In the area 
of oncology, eight studies have mapped EQ-5D from the 
FACIT questionnaires: three studies [11, 22, 27] mapped the 
general FACT-G version in various types of cancer (includ-
ing lung cancer); another three algorithms [19, 21, 28] used 
the prostate-specific (FACT-P) module, while the remain-
ing two adopted the melanoma-specific (FACT-M) [29] and 
breast-specific (FACT-B) [30] versions. Until now, no algo-
rithms were available to map EQ-5D scores from FAACT, 
which is the FACIT tool specifically aimed at measuring 
HRQoL in patients with cancer cachexia; nor is there a 
mapping algorithm for the FACIT-F. Moreover, the existing 
algorithms map to the EQ-5D-3L rather than the EQ-5D-5L; 
thus, it was not possible to apply these functions to our data-
base of EQ-5D-5L utilities. In addition, most mapping stud-
ies have used cross-sectional data and Ordinary Least Square 
(OLS) regression in modeling FACIT scores; even when 
data from multiple time points were available, only baseline 
information were used [21] or repeated observations were 
pooled together in order to increase the sample size [31].
This study, following the approach of a previous one 
[19], estimated GEE models to account for the longitudinal 
nature of the data. To increase the usability of the mapping 
algorithms, common demographics (e.g. age) and clinical 
variables (e.g. BMI), which are likely to be collected in clini-
cal studies dealing with cancer cachexia or NSCLC were 
initially tested in the models. Among them, only ECOG per-
formance score displayed a significant coefficient (p < 0.05) 
and was retained in the final models. Moreover, in addition 
to developing a mapping function to predict EQ-5D-5L utili-
ties from FAACT and FACIT-F, we provided separate algo-
rithms for the general instrument (FACT-G). Disaggregated 
models predicting EQ-5D-5L utility values from individual 
FACIT subscales were found to have better predictive ability 
in the case of FACT-G and FAACT, while the best perform-
ing algorithm for FACIT-F was that modeling the TOI score. 
These results are aligned with the current mapping literature 
which has shown greater explanatory power from regres-
sion models using disaggregated information instead of 
summary scores from a disease-specific measure [22]. Nev-
ertheless, all the algorithms performed quite well; overall, 
MAE and RMSE values were comparable across the models 
and lower than those reported by other mapping studies [19, 
24, 32]. No considerable differences were found between 
the algorithms developed using the English and the Dutch 
value sets, which identified the same best performing models 
(Model 3, Model 3, Model 4) within each FACIT instru-
ment; however, mapping using English weights performed 
slightly better in terms of lower MAE/RMSE and smaller 
differences between mean observed and mean predicted EQ-
5D-5L utilities. The estimated coefficients are aligned with 
those reported by a previous study [11] mapping FACT-
G in cancer patients affected by breast, colorectal or lung 
cancer, where regression coefficients for the overall score 
were between 0.005 and 0.008 (according to the technique 
adopted) and coefficients for individual subscales fell in 
the interval 0.006–0.013 for PWB, 0.005–0.010 for FWB, 
0.002–0.008 for EWB. Our slightly lower estimates may be 
a consequence of the different regression method (GEEs) 
applied, or possibly is reflecting differences in the patient 
groups, for example, in terms of severity.
This study presents a few limitations. First, in calculat-
ing EQ-5D-5L utilities, we adopted country preference 
weights that may not be the best estimates for Hungarian 
and Polish populations. However, due to unavailability of 
EQ-5D-5L tariffs for these two countries, we selected the 
SD standard deviation, FACT-G Functional assessment of cancer therapy-general, FACIT functional assessment of chronic illness therapy, 
FAACT functional assessment of anorexia/cachexia treatment, FACIT-F functional assessment of chronic illness therapy-fatigue, PWB physical 
wellbeing, FWB functional wellbeing, EWB emotional wellbeing, SWB social/family wellbeing, ACS Anorexia-Cachexia Subscale, TOI trial out-
come index, EQ-5D-5L EuroQol five-dimension five-level, UK United Kingdom, NL Netherlands
Table 2  (continued)
Instrument Statistics Baseline Week 3 Week 6 Week 9 Week 12
 EQ-5D-5L utility (NL index)
Theoretical range (min, max): −0.446, 
1
N 96 88 85 77 74
Mean (±SD) 0.702 (±0.23) 0.736 (±0.22) 0.744(±0.23) 0.752(±0.19) 0.709(±0.25)
Range (min, max) −0.289, 1.000 −0.077, 1.000 −0.391, 1.000 0.195, 1.000 −0.326, 1.000
% floor, % ceiling 0.0, 10.4 0.0, 18.2 0.0, 18.8 0.0, 18.2 0.0, 17.6
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Fig. 1  a Scatterplot of observed versus predicted EQ-5D-5L utility 
across all visits using the best performing models (validation sample, 
UK weights). b Scatterplot of observed versus predicted EQ-5D-5L 
utility across all visits using the best performing models (validation 
sample, NL weights)
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Table 3  GEE coefficient estimates (development sample)
Model 1 Model 2 Model 3 Model 4 Model 5
β SE β SE β SE β SE β SE
(a) UK weights
 FACT-G
  Intercept 0.5387*** 0.0485 – – 0.6185*** 0.0517 – –
  FACT-G 0.0041*** 0.0007 – – – –
  PWB – – 0.0094*** 0.0019 – –
  FWB – – 0.0052** 0.0019 – –
  SWB – – −0.0044* 0.0022 – –
  EWB – – 0.0035 0.0022 – –
  ECOG −0.1865*** 0.0321 – – −0.1586*** 0.0310 – –
 FAACT
  Intercept 0.4952*** 0.0467 0.5088*** 0.0474 0.5841*** 0.0524 0.5210*** 0.0392 0.5240*** 0.0390
  FAACT 0.0033*** 0.0004
  FACT-G 0.0022** 0.0008
  PWB 0.0071** 0.0021 0.0077*** 0.0020
  FWB 0.0040* 0.0020 0.0030 0.0018
  SWB −0.0042 0.0022
  EWB 0.0021 0.0023
  ACS 0.0051*** 0.0013 0.0035** 0.0013 0.0037** 0.0013
  TOI 0.0046*** 0.0006
  ECOG −0.1738*** 0.0310 −0.1702*** 0.0308 −0.1524*** 0.0304 −0.1607*** 0.0305 −0.1584*** 0.0304
 FACIT-F
  Intercept 0.5000*** 0.0433 0.5604*** 0.0461 0.6157*** 0.0503 0.5290*** 0.0357 0.5442*** 0.0363
  FACIT-F 0.0033*** 0.0004
  FACT-G 0.0006 0.0009
  PWB 0.0041 0.0022 0.0045* 0.0022
  FWB 0.0029 0.0020 0.0017 0.0018
  SWB −0.0048* 0.0021
  EWB 0.0010 0.0022
  Fatigue 0.0074*** 0.0013 0.0059*** 0.0014 0.0058*** 0.0013
  TOI 0.0047*** 0.0005
  ECOG −0.1711*** 0.0310 −0.1611*** 0.0307 −0.1484*** 0.0305 −0.1568*** 0.0305 −0.1553*** 0.0303
(b) NL weights
 FACT-G
  Intercept 0.4443*** 0.0569 0.5390*** 0.0609
  FACT-G 0.0049*** 0.0008
  PWB 0.0107*** 0.0022
  FWB 0.0066** 0.0023
  SWB −0.0051* 0.0026
  EWB 0.0037 0.0026
  ECOG −0.2225*** 0.0385 −0.1906*** 0.0377
 FAACT
  Intercept 0.3956*** 0.0549 0.4098*** 0.0558 0.4993*** 0.0618 0.4263*** 0.0462 0.4291*** 0.0459
  FAACT 0.0038*** 0.0005
  FACT-G 0.0027** 0.0010
  PWB 0.0082** 0.0024 0.0088*** 0.0023
  FWB 0.0052* 0.0023 0.0040 0.0021
  SWB −0.0048 0.0025
  EWB 0.0021 0.0026
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English value set (mappings to the EQ-5D-3L have most 
commonly used this set) and the Dutch one, which are the 
two EQ-5D-5L sets of weights closest to the ROMANA 
trials populations [7].
Second, model validation used a non-random split-sample 
method, rather than testing the algorithms in an external 
dataset that would be the preferred approach according to 
the MAPS Statement [13]. However, significant differences 
were found in relevant baseline patients characteristics (i.e. 
BMI, weight loss, ECOG, chemotherapy/radiotherapy sta-
tus) between the two samples, thus the cross-sample valida-
tion was likely to have been conducted on a quasi-different 
NSCLC-C population. A completely different approach has 
been suggested by most recent guidelines [33], which rec-
ommend not splitting the sample for validation purposes if 
this implies a further reduction of a (small) sample size.
Third, the mapping functions were developed using 
a small database, since only 96 patients enrolled in the 
ROMANA trials were invited to complete the EQ-5D-5L. 
However, because the patients completed the HRQoL ques-
tionnaires on up to five occasions, 420 observations were 
available for analysis, 79% (n = 332) of which were used to 
obtain regression coefficients and 21% (n = 88) to validate 
the mapping algorithms.
Fourth, the sample of NSCLC-C patients who were likely 
to have a better health status (i.e. ECOG ≤2, life expectancy 
at least of 4 months) than the general population with the 
same medical condition due to the ROMANA trials’ inclu-
sion criteria. Thus, the generalizability of the developed 
mapping functions to other NSCLC-C samples should con-
sider any potential clinical differences.
Finally, as already observed in the literature [11, 34], all 
mapping algorithms tend to over-predict utility values for 
patients in poor health and, conversely, under-predict the 
highest scores. Moreover, they systematically fail to predict 
the value of 1 corresponding to perfect health, although in 
our database, due to the severity of the NSCLC-C condi-
tion, less than 20% of EQ-5D-5L observations were at the 
ceiling at each study visit, which is lower than observed 
in another mapping study using the same tool [30]. This 
bias affected the FACIT-F algorithms less than FACT-G 
and FAACT ones and, within the same FACIT instrument, 
models using disaggregated scales (Model 3) instead of sum-
mary scores (Model 1). Skaltsa et al. [19] developed group-
specific models according to disease severity to increase 
prediction accuracy at the “extremes”; unfortunately, due to 
the small database, this approach was infeasible in this study. 
As population-average models, the estimated GEE functions 
ECOG is a dummy variable assuming the value of 1 for ECOG = 2 and 0 otherwise (ECOG = 0.1)
Model 1 algorithm using FACIT overall score(s), Model 2 algorithm using general (FACT-G) and questionnaire-specific scale(s) separately, 
Model 3 algorithm using the four FACT-G wellbeing subscales, Model 4 algorithm using FACIT TOI score(s), Model 5 algorithm using TOI 
subscales separately, GEE generalized estimating equations, UK United Kingdom, NL Netherlands, SE standard error, FACT-G functional 
assessment of cancer therapy-general, FAACT functional assessment of anorexia/cachexia treatment, FACIT-F functional assessment of chronic 
illness therapy-fatigue, PWB physical wellbeing, FWB functional wellbeing, EWB emotional wellbeing, SWB social/family wellbeing, ACS Ano-
rexia-Cachexia Subscale, TOI trial outcome index, ECOG Eastern Cooperative Oncology Group
*p value <0.05
**p value <0.01
***p value <0.001
Table 3  (continued)
Model 1 Model 2 Model 3 Model 4 Model 5
β SE β SE β SE β SE β SE
  ACS 0.0057*** 0.0015 0.0039* 0.0015 0.0042** 0.0015
  TOI 0.0054*** 0.0007
  ECOG −0.2078*** 0.0372 −0.2040*** 0.0371 −0.1834*** 0.0370 −0.1925*** 0.0368 −0.1901*** 0.0367
 FACIT-F
  Intercept 0.4019*** 0.0510 0.4673*** 0.0543 0.5350*** 0.0593 0.4364*** 0.0421 0.4520*** 0.0428
  FACIT-F 0.0038*** 0.0005
  FACT-G 0.0010 0.0010
  PWB 0.0048 0.0026 0.0054* 0.0025
  FWB 0.0040 0.0023 0.0026 0.0021
  SWB −0.0055* 0.0025
  EWB 0.0010 0.0026
  Fatigue 0.0083*** 0.0015 0.0065*** 0.0016 0.0064*** 0.0015
  TOI 0.0054*** 0.0006
  ECOG −0.2050*** 0.0374 −0.1944*** 0.0372 −0.1792*** 0.0372 −0.1884*** 0.0370 −0.1870*** 0.0368
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performed well in predicting mean utility values, which are 
usually required to populate model-based economic evalua-
tions. New techniques such as beta-binomial regression and 
limited dependent variable mixture (LDVM) models [22, 23, 
35], which better fit the typical distributions of EQ-5D data, 
are emerging in the mapping literature to overcome the well-
known limitations of linear models and might be explored in 
future research with larger databases.
Conclusion
Given the increasing costs of cancer care it is important 
to support the health-related decision-making process 
of allocating scarce resources by assessing the value of 
treatments through economic evaluation techniques such 
as cost-utility analysis [36]. Previous research showed that 
cancer cachexia, mainly affecting lung cancer patients, has 
Table 4  Synthesis of model performance across all visits (validation sample)
UK United Kingdom, NL Netherlands, SD standard deviation, FACT-G functional assessment of cancer therapy-general, FAACT functional 
assessment of anorexia/cachexia treatment, FACIT-F functional assessment of chronic illness therapy-fatigue, MAE mean absolute error, RMSE 
root mean squared error
a T test
Mean (±SD) Range (min, max) % floor, % ceiling Mean observed − mean 
predicted (p  valuea)
MAE RMSE
(a) UK weights
 Observed 0.809 (±0.16) 0.128, 1.000 0.0, 14.8 – – –
 FACT-G
  Model 1 0.816 (±0.06) 0.590, 0.953 0.0, 0.0 −0.0070 (0.7017) 0.0997 0.1339
  Model 3 0.832 (±0.07) 0.583, 0.970 0.0, 0.0 −0.0226 (0.2335) 0.0942 0.1272
 FAACT
  Model 1 0.827 (±0.06) 0.645, 0.984 0.0, 0.0 −0.0178 (0.3393) 0.1027 0.1366
  Model 2 0.825 (±0.06) 0.646, 0.971 0.0, 0.0 −0.0161 (0.3857) 0.1064 0.1412
  Model 3 0.835 (±0.07) 0.638, 0.987 0.0, 0.0 −0.0259 (0.1722) 0.0995 0.1332
  Model 4 0.819 (±0.07) 0.641, 0.967 0.0, 0.0 −0.0100 (0.5927) 0.1027 0.1362
  Model 5 0.831 (±0.07) 0.652, 0.979 0.0, 0.0 −0.0219 (0.2455) 0.1015 0.1340
 FACIT-F
  Model 1 0.831 (±0.07) 0.544, 0.998 0.0, 0.0 −0.0223 (0.2417) 0.0933 0.1267
  Model 2 0.843 (±0.08) 0.575, 0.991 0.0, 0.0 −0.0343 (0.0761) 0.0942 0.1288
  Model 3 0.844 (±0.08) 0.577, 1.014 0.0, 1.1 −0.0351 (0.0729) 0.0913 0.1261
  Model 4 0.833 (±0.08) 0.543, 0.999 0.0, 0.0 −0.0241 (0.2161) 0.0899 0.1230
  Model 5 0.842 (±0.08) 0.553, 0.998 0.0, 0.0 −0.0328 (0.0917) 0.0917 0.1257
(b) NL weights
 Observed 0.760 (±0.19) −0.073, 1.000 0.0, 14.8 – – –
 FACT-G
  Model 1 0.766 (±0.07) 0.505, 0.939 0.0, 0.0 −0.0161 (0.4561) 0.1094 0.1574
  Model 3 0.784 (±0.08) 0.499, 0.945 0.0, 0.0 -0.0245 (0.2719) 0.1068 0.1503
 FAACT
  Model 1 0.778 (±0.07) 0.568, 0.958 0.0, 0.0 −0.0178 (0.2991) 0.1131 0.1601
  Model 2 0.780 (±0.07) 0.572, 0.950 0.0, 0.0 −0.0200 (0.2586) 0.1174 0.1651
  Model 3 0.788 (±0.08) 0.567, 0.964 0.0, 0.0 −0.0280 (0.0932) 0.1112 0.1566
  Model 4 0.776 (±0.08) 0.567, 0.950 0.0, 0.0 −0.0165 (0.3365) 0.1145 0.1605
  Model 5 0.787 (±0.08) 0.576, 0.961 0.0, 0.0 −0.0266 (0.1118) 0.1126 0.1571
 FACIT-F
  Model 1 0.784 (±0.08) 0.453, 0.976 0.0, 0.0 −0.0238 (0.1329) 0.1026 0.1481
  Model 2 0.807 (±0.09) 0.488, 0.983 0.0, 0.0 −0.0471 (0.0030) 0.1051 0.1515
  Model 3 0.797 (±0.10) 0.492, 0.992 0.0, 0.0 −0.0370 (0.0175) 0.1030 0.1471
  Model 4 0.786 (±0.10) 0.453, 0.976 0.0, 0.0 −0.0262 (0.0885) 0.1007 0.1440
  Model 5 0.798 (±0.09) 0.464, 0.980 0.0, 0.0 −0.0383 (0.0132) 0.1020 0.1464
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a significant impact on patients HRQoL and healthcare 
resources utilization [10]. This study provided algorithms 
to predict EQ-5D-5L utility values from FACT-G, FAACT 
and FACIT-F scores, confirming that mapping may rep-
resent a useful tool in the absence of preference-based 
HRQoL scores. These algorithms could be applied in other 
studies related to cancer cachexia or NSCLC in general, 
by those requiring EQ-5D-5L utility values for QALY 
calculation.
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